Lifesciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those lifesciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.
Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Lifesciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it sound out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area


    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more


    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more


    The healthcare sector in the UK and internationally continues to experience a period of dynamic change underpinned by significant legal reforms and devolution to the four British nations. As an owner, operator or service provider in this sector, you are facing a highly regulated environment combined with increased public scrutiny. With increasing opportunities for the private provision of healthcare along with an ageing population, but with shrinking public healthcare budgets, operating within the healthcare sector presents both challenges and opportunities.

    Read more


    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    Highlights of our experience in Lifesciences in th...
    Law-Now: Lifesciences
    Visit Law-Now for legal know-how and commentary


    Show only
    1 May 2017
    CMS, Nabarro and Olswang complete largest ever mer...
    Creating a new future-facing firm
    European Commission investigates potential excessive pricing of l...
    On 15 May 2017, the European Commission opened a formal investigation into the pricing of medicines. [1] The Commission is investigating whether Aspen Pharma has been imposing excessive pricing that constitutes an abuse of dominant position in violation of European.
    21 March 2017
    Olswang advises two new VC clients on Series B inv...
    Brexit one year on: The Unified Patent Court
    The Unified Patent Court (“UPC”) has been edging closer to reality in recent years and the UK was set to play a major role. The UPC aims to provide an easier and more cost-effective way to protect and exploit patent rights in Europe, and patents in the life.
    7 March 2017
    Olswang advises IP support services business RWS H...
    The Court of Justice of the EU held that the Belgian general proh...
    On 4 May 2017, the Court of Justice of the EU answered several prejudicial questions submitted by the Belgian tribunal of first instance regarding the advertising of the services of dentists. In this judgment, the Court held that the Belgian legislation imposing.
    14 February 2017
    Health Tech 2017: a case for greater connection
    The Verdict - Round-up of corporate crime developments across CMS
    We are pleased to send our new issue of The Verdict, an at-a-glance round-up of recent legal developments in relation to corporate crime. In this issue, the spotlight is on some significant changes to anti-corruption laws in the Czech Republic, including.
    13 December 2016
    CMS, Nabarro and Olswang confirm Practice and Sect...
    Continued Focus on Pricing in the Pharma Sector
    Recent announcements by both the UK Competition & Markets Authority (CMA) and the European Commission in relation to investigations in the pharmaceutical sector demonstrate that anti-competitive pricing remains an enforcement priority.
    11 November 2016
    12 Olswang partners recognised as Band 1 in Chambe...
    SFO overcomes privilege claim for internal investigation document...
    Summary The High Court has held that certain documents created by legal and other advisers of Eurasian National Resources Ltd (“ENRC”) during an internal investigation into allegations of wrongdoing, are not protected by legal professional privilege.
    10 October 2016
    CMS, Nabarro and Olswang combine to create 6th lar...
    New regulation on medical devices
    Introduction The current legal framework for medical devices in the European Union is based on the following Directives, adopted in the 1990s: §  Directive 90/385/EEC, active implantable medical devices §  Directive 93/42/EEC, medical devices §  Directive.
    10 October 2016
    CMS, Nabarro and Olswang combine to create 6th lar...
    EU Medical Devices Regulation and In-Vitro Medical Devices Regula...
    The EU Medical Devices Regulation and In-Vitro Medical Devices Regulation (the “Regulations”) were adopted on 5 April 2017, following a final vote at the European Parliament. The Regulations were proposed by the Commission in 2012 (as discussed in our previous.
    15 September 2016
    Olswang's status as a leading TMT firm again ackno...
    EMA & HMA establish task force to explore big data's potential fo...
    A new task force has been set up to explore how medicines regulators in the EU can use big data to improve human and animal health. The task force has been established by the European Medicines Agency (“EMA”), in conjunction with the EEA Heads of Medicines.